This is to inform you under Regulation 30 and any other regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Board of Directors of the Company ....
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals' board met on August 16, 2025 and approved the Board of Directors' Report for FY ending March 31, 2025 along with the Notice of the 42nd Annual General Meeting, which is scheduled for Tuesday, September 9, 2025 at 12:00 noon via video conferencing. The book closure period is set for September 2 to September 9, 2025, and e-voting via NSDL will run from September 6 (9:00 AM) to September 8 (5:00 PM), with September 1, 2025 as the cut-off date. The board approved re-appointments of Mr. Ramesh Arora as Managing Director, Mr. Ajay Kumar Arora, Mrs. Anju Arora, and Mrs. Geeta Arora as Whole Time Directors, each for a 5-year term starting January 16, 2026. Also re-appointed Mr. Kartik Kapur for a second 5-year term as Independent Director, regularized Mr. Vinod Kumar Sharma's appointment as Independent Director, and appointed M/s Rishi Mittal & Associates as Secretarial Auditor for FY 2025-26 through FY 2029-30.
These are routine governance and leadership continuity decisions with no major strategic shifts; all director re-appointments require shareholder approval at the September 9, 2025 AGM. Stock price impact is expected to be neutral as the re-appointments mainly retain the existing promoter-family-led management structure.